Ntisec ☑️Nov 25, 2022

Interesting trial.

Long-COVID personalized medicine enters Phase 2 trial using #Temelimab against #HERV virus that was induced during a SARScov2 infection in #LongCovid patients. #Anti_W_ENV
https://www.biopharma-reporter.com/Article/2022/11/22/Long-COVID-personalized-medicine-enters-Phase-2-trial#.Y33omibPgA0.twitter

Long-COVID personalized medicine enters Phase 2 trial

GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue.

biopharma-reporter.com